Effects of Canagliflozin combined with Metformin and Irbesartan in treatment of middle-aged and elderly patients with type 2 diabetes mellitus complicated with renal injury
Objective:To observe effects of Canagliflozin combined with Metformin and Irbesartan in treatment of middle-aged and elderly patients with type 2 diabetes mellitus(T2DM)complicated with renal injury.Methods:The clinical data of 60 middle-aged and elderly patients with T2DM complicated with renal injury admitted to this hospital from June 2022 to May 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group(n=30)and study group(n=30).The control group was treated with Metformin combined with Irbesartan,while the study group was treated with Canagliflozin on the basis of that of the control group.The levels of islet function indexes(insulin sensitivity index,islet β cell function index,insulin resistance index),glucose and lipid metabolism indexes[fasting blood glucose(FPG),2 h postprandial blood glucose(2hPG),total cholesterol(TC),triglyceride(TG)]and renal function indexes[24 h urine protein quantification(24hUP),serum creatinine(Scr),blood urea nitrogen(BUN)].and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of insulin sensitivity index and islet β cell function index in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the insulin resistance index levels of the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).The levels of FPG,2hPG,TC and TG in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of 24hUP,Scr and BUN in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Canagliflozin combined with Metformin and Irbesartan in the treatment of the middle-aged and elderly patients with T2DM complicated with renal injury can improve the levels of islet function indexes and reduce the levels of glucose and lipid metabolism indexes and renal function indexes.Moreover,it is superior to Metformin combined with Irbesartan treatment.
CanagliflozinMetforminIrbesartanType 2 diabetes mellitusMiddle-aged and elderlyIslet functionGlucose and lipid metabolism
万方数据
维普
